|Dr. Eric E. Poma||CEO, Chief Scientific Officer & Director||606.54k||N/A||1972|
|Ms. Jason S Kim||Pres & COO||444.74k||N/A||1975|
|Mr. Adam D. Cutler B.A.||Chief Financial Officer||N/A||N/A||1974|
|Mr. Kurt Elster||Exec. VP of Corp. Devel.||N/A||N/A||1967|
|Dr. Jack Higgins Ph.D.||Exec. VP of Operations & Head of Manufacturing||N/A||N/A||1980|
Molecular Templates, Inc., a clinical stage oncology company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other diseases. The company primarily develops a pipeline of engineered toxin bodies. Its lead drug candidate is MT-3724 that is in a Phase II clinical trial for the treatment of relapsed/refractory diffuse large B-cell lymphoma; and Phase II clinical trial for treating non-Hodgkin's lymphoma. The company also develops MT-4019, engineered toxin body targeting CD38; and TAK-169 targeting CD38. It has an agreement with Takeda Pharmaceutical Company Limited to develop CD38-targeted engineered toxin bodies for the treatment of patients with diseases, such as multiple myeloma. Molecular Templates, Inc. is headquartered in Austin, Texas.
Molecular Templates, Inc.’s ISS Governance QualityScore as of October 4, 2019 is 9. The pillar scores are Audit: 5; Board: 10; Shareholder Rights: 6; Compensation: 7.